<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02710500</url>
  </required_header>
  <id_info>
    <org_study_id>IRB15-00669</org_study_id>
    <nct_id>NCT02710500</nct_id>
  </id_info>
  <brief_title>rAAVrh74.MHCK7.DYSF.DV for Treatment of Dysferlinopathies</brief_title>
  <official_title>Phase I Intramuscular Gene Transfer Clinical Trial for Dysferlin Deficiency Delivering the Dysferlin Gene by AAVrh74</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sarepta Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sarepta Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed clinical trial is a double-blind, randomized controlled study with direct&#xD;
      intramuscular injection of rAAVrh.74.MHCK7.DYSF.DV gene vector to the extensor digitorum&#xD;
      brevis muscle (EDB). Two cohorts of subjects with dysferlin deficiency, each with proven&#xD;
      mutations will undergo gene transfer. A minimum of three subjects will be enrolled into each&#xD;
      cohort.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase I safety and tolerability study with a direct intramuscular injection of&#xD;
      rAAVrh.74.MHCK7.DYSF.DV transferred to the extensor digitorum brevis muscle (EDB). The study&#xD;
      is designed as a randomized, controlled, dose escalation trial with one EDB receiving the&#xD;
      rAAVrh.74.MHCK7.DYSF.DV and the other side receiving saline alone. It will follow the&#xD;
      previously safe and effective IM gene transfer to EDB for LGMD2D.2, 3 The first cohort,&#xD;
      inclusive of three Dysferlinopathy subjects, will receive a gene transfer total dose of 2 x&#xD;
      10^12 vector genomes. Muscle biopsies will be performed at Day 45 (two subjects) and Day 90&#xD;
      (one subject). If there are no safety concerns, three additional subjects will be enrolled&#xD;
      and receive an escalated dose at 6 X 10^12 vg (total dose). Muscle biopsies in the second&#xD;
      cohort will be performed at Day 90 (one subject) and Day 180 (two subjects). This protocol&#xD;
      design gives us a maximum period of observation ranging from 6 weeks to 6 months to capture&#xD;
      both transient and delayed gene expression, and to recognize sustained expression.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Actual">July 2019</completion_date>
  <primary_completion_date type="Actual">July 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determination of safety based on the development of unacceptable toxicity</measure>
    <time_frame>2 Years</time_frame>
    <description>Defined as the occurrence of any one Grade III or higher, unanticipated, treatment-related toxicity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants showing dysferlin protein expression in muscle tissue</measure>
    <time_frame>2 Years</time_frame>
    <description>More than 3 fold increase in dysferlin protein expression in muscle compared to control side by western blot or more than 30% increase in dysferlin-expressing fibers&#xD;
Dysferlin protein expression as demonstrated with N -terminal anti-dysferlin antibodies will be quantified using BioQuant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leukocyte marker counts including CD45, CD3, CD4, CD8, and MAC 387.</measure>
    <time_frame>2 Years</time_frame>
    <description>Number of CD4+ cells/ mm2 area; Number of CD8+ cells/ mm2 area; Number of muscle fibers expressing MHCI staining / mm2 area; Number of muscle fibers expressing MHCII staining / mm2 area</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Binding antibodies counts and ELISpot counts to both rAAVrh74 capsid and dysferlin protein.</measure>
    <time_frame>2 Years</time_frame>
    <description>AAVrh74 or AAV8 binding antibody titers &gt; 1:50 as determined by ELISA immunoassay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of inflammatory cells in muscle</measure>
    <time_frame>2 Years</time_frame>
    <description>Number of inflammatory cells per mm2 area</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Dysferlinopathy</condition>
  <arm_group>
    <arm_group_label>Cohort 1 (Low Dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three (n=3) dysferlin deficiency subjects will receive bilateral injections with one extensor digitorum brevis muscle (EDB) receiving the rAAVrh74.MHCK7.DYSF.DV and the other side receiving saline alone.Subjects will receive a total dose of 2 x 10^12 in one muscle.&#xD;
Intervention Drug: rAAVrh.MHCK7.DYSF.DV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 (High Dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three (n=3) dysferlin deficiency subjects will receive bilateral injections with one extensor digitorum brevis muscle (EDB) receiving the rAAVrh74.MHCK7.DYSF.DV and the other side receiving saline alone.Subjects will receive a total dose of 6 x 10^12 vg in one muscle.&#xD;
Intervention Drug: rAAVrh74.MHCK7.DYSF.DV</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rAAVrh74.MHCK7.DYSF.DV</intervention_name>
    <description>Biological/Vaccine: rAAVrh74.MHCK7.DYSF.DV Recombinant adeno-associated virus carrying a dysferlin transgene under control of a muscle specific MHCK7 promoter.</description>
    <arm_group_label>Cohort 1 (Low Dose)</arm_group_label>
    <arm_group_label>Cohort 2 (High Dose)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Must be Non-ambulant (cannot walk 10 meters in ≤ 30 sec) and age 18 years or older&#xD;
&#xD;
          -  Established mutations of the dysferlin gene on both alleles&#xD;
&#xD;
          -  Impaired muscle function but with sufficient muscle preservation to ensure muscle&#xD;
             transfection based on magnetic resonance image of the EDB showing sufficient muscle&#xD;
             preservation to permit transfection&#xD;
&#xD;
          -  Willingness of sexually active subjects with reproductive capacity to practice&#xD;
             reliable method of contraception (If appropriate), during the first six months after&#xD;
             gene transfer (females) or until two negative sperm samples are obtained post gene&#xD;
             transfer (males).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active viral infection based on clinical observations or serological evidence of HIV,&#xD;
             or Hepatitis A, B or C infection&#xD;
&#xD;
          -  The presence of a Dysferlin mutations without weakness or loss of function&#xD;
&#xD;
          -  Symptoms or signs of cardiomyopathy, including:&#xD;
&#xD;
          -  Dyspnea on exertion, pedal edema, shortness of breath upon lying flat, or rales at the&#xD;
             base of the lungs&#xD;
&#xD;
          -  Echocardiogram with ejection fraction below 40%&#xD;
&#xD;
          -  Diagnosis of (or ongoing treatment for) an autoimmune disease&#xD;
&#xD;
          -  Persistent leukopenia or leukocytosis (WBC ≤ 3.5 K/µL or ≥ 20.0 K/µL) or an absolute&#xD;
             neutrophil count &lt; 1.5K/µL&#xD;
&#xD;
          -  Concomitant illness or requirement for chronic drug treatment that in the opinion of&#xD;
             the PI creates unnecessary risks for gene transfer&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  AAVrh74 or AAV8 binding antibody titers &gt; 1:50 as determined by ELISA immunoassay&#xD;
&#xD;
          -  Abnormal laboratory values in the clinically significant range in the table below,&#xD;
             based upon normal values in the Nationwide Children's Hospital Laboratory: GGT, Total&#xD;
             Bilirubin, Cystatine, Hemoglobin, White Blood Cells&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jerry R Mendell, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Director, Center for Gene Therapy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nationwide Children's Hosptial</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.nationwidechildrens.org/center-for-gene-therapy</url>
    <description>Center for Gene Therapy, The Research Institute at Nationwide Children's Hospital</description>
  </link>
  <reference>
    <citation>Sondergaard PC, Griffin DA, Pozsgai ER, Johnson RW, Grose WE, Heller KN, Shontz KM, Montgomery CL, Liu J, Clark KR, Sahenk Z, Mendell JR, Rodino-Klapac LR. AAV.Dysferlin Overlap Vectors Restore Function in Dysferlinopathy Animal Models. Ann Clin Transl Neurol. 2015 Mar;2(3):256-70. doi: 10.1002/acn3.172. Epub 2015 Jan 20.</citation>
    <PMID>25815352</PMID>
  </reference>
  <reference>
    <citation>Grose WE, Clark KR, Griffin D, Malik V, Shontz KM, Montgomery CL, Lewis S, Brown RH Jr, Janssen PM, Mendell JR, Rodino-Klapac LR. Homologous recombination mediates functional recovery of dysferlin deficiency following AAV5 gene transfer. PLoS One. 2012;7(6):e39233. doi: 10.1371/journal.pone.0039233. Epub 2012 Jun 15.</citation>
    <PMID>22720081</PMID>
  </reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>February 11, 2016</study_first_submitted>
  <study_first_submitted_qc>March 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 16, 2016</study_first_posted>
  <last_update_submitted>May 11, 2021</last_update_submitted>
  <last_update_submitted_qc>May 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>LGMD2B</keyword>
  <keyword>Limb Girdle Muscular Dystrophy</keyword>
  <keyword>Miyoshi</keyword>
  <keyword>Gene Transfer</keyword>
  <keyword>Dysferlin</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

